<DOC>
	<DOCNO>NCT02651259</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics , tolerability , safety once-weekly dos rifapentine ( RPT ) isoniazid ( INH ) HIV-1-infected HIV-1-uninfected pregnant postpartum woman latent tuberculosis ( TB ) .</brief_summary>
	<brief_title>Evaluating Pharmacokinetics , Tolerability , Safety Once-Weekly Rifapentine Isoniazid HIV-1-Infected HIV-1-Uninfected Pregnant Postpartum Women With Latent Tuberculosis Infection</brief_title>
	<detailed_description>TB major cause illness death woman reproductive age . Pregnant postpartum woman latent TB high risk develop active TB . This study evaluate pharmacokinetics , tolerability , safety 12 once-weekly dos RPT INH HIV-1-infected HIV-1-uninfected pregnant postpartum woman latent TB . This study enroll HIV-1-infected HIV-1-uninfected pregnant woman latent TB infant two cohort base gestation . Cohort 1 participant enrol second trimester ( great equal 14 less 28 week ) , Cohort 2 participant enrolled third trimester ( great equal 28 less equal 34 week ) . All participant receive 12 directly observe once-weekly dos RPT , INH , pyridoxine ( vitamin B6 ) study visits week 1-12 . Study researcher perform interim analysis study , dose adjustment may recommend base analysis . Study visit occur day 0-3 , week week 1-12 , month 24 week delivery . Visits include physical examination , obstetrical exam , blood collection . Infants follow monthly 24 week birth .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Latent Tuberculosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Rifapentine</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Age great equal 18 year , minimum age consent accord locally applicable law regulation screen , verify per site standard operating procedure ( SOPs ) ; able willing provide write informed consent study screen At screening , evidence ultrasound viable singleton pregnancy estimate gestational age enrollment great equal 14 week less equal 34 week per screen ultrasound ( see protocol information ) Has least one follow risk factor TB : Per participant report , participant household contact* know active pulmonary TB patient Per medical record , confirmation HIV1 infection ( see protocol information ) single positive tuberculin skin test ( TST ) interferon gamma release assay ( IGRA ) time past . If available medical record , perform screen . Note : A household contact define person currently live live dwell unit share share housekeep arrangement report exposure within past two year adult index case pulmonary TB . Shared housekeep arrangement define sleep roof index TB case least seven consecutive day one month prior index case TB diagnosis . Documentation HIV1 infection status , confirmation HIV1 infection status ( unknown undocumented ) . Confirmation HIV1 infection define positive result two sample ( describe protocol ) collect different time point . All sample test must whole blood , serum , plasma . As study conduct IND , test method FDAapproved , available . If FDAapproved method available , test method verify accord Good Clinical Laboratory Practice ( GCLP ) approve IMPAACT Laboratory Center . More information criterion available protocol . If HIV1infected , document current prescription efavirenz ( EFV ) + 2 nucleoside reverse transcriptase inhibitor ( NRTI ) regimen report take regimen least two week prior enrollment ( regimens contain protease , integrase , entry inhibitor permit ) Documented laboratory value obtain within 14 day prior enrollment : Hemoglobin great equal 7.5 g/dL White blood cell count great equal 1,500 cells/mm^3 Alanine transaminase ( ALT ) less 2.5 time upper limit normal ( ULN ) Total bilirubin less 1.6 time ULN Absolute neutrophil count ( ANC ) great equal 750 cells/mm^3 Platelet count great equal 100,000/mm^3 Per participant report screening , intent remain current geographical area residence duration study Per participant report screening , able swallow whole tablet Per participant report , intention keep pregnancy Per participant report , willingness permit infant participate study Evidence confirm probable active TB disease per World Health Organization ( WHO ) symptom screen confirmation Gene Xpert , shield chest xray , sputum sample Participant report personal history INH rifampinresistant , multidrug resistant ( MDR ) , extensively drugresistant ( XDR ) TB Participant report personal history active TB past 2 year Participant report previous treatment latent tuberculosis infection ( LTBI ) Household contact ( define ) know active MDR XDR TB disease Known major fetal abnormality detect ultrasound Known allergy/sensitivity hypersensitivity component study drug formulation Known history liver cirrhosis time prior study entry Per participant report and/or medical record , evidence acute clinical hepatitis , combination abdominal pain , jaundice , dark urine , and/or light stool within 90 day prior entry Participant report and/or medical record peripheral neuropathy Grade 2 high within 90 day prior entry Current use history active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement Participant report and/or clinical evidence porphyria Any condition , opinion investigator record ( IoR ) /designee , would preclude informed consent , make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective , include take study medication Planned current participation interventional drug study Current use prohibit precautionary medication ( see protocol information ) , include didanosine ( DDI ) stavudine ( D4T )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>